|
[1] Chinese Society of Hepatology,Chinese Medical Association;Chinese Society of Gastroenterology,Chinese Medical Association; Chinese Society of Endoscopy,Chinese Medical Association. Guidelines for the prevention and treatment of esophageal and gastric varices bleeding in cirrhotic portal hypertension[J]. J Clin Hepatol,2016,32(2):203-219.(in Chinese)中华医学会肝病学分会，中华医学会消化病学分会，中华医学会内镜学分会．肝硬化门静脉高压食管胃静脉曲张出血的防治指南[J]．临床肝胆病杂志，2016,32(2):203-219.
|
|
[2] BAFFY G. Potential mechanisms linking gut microbiota and portal hypertension[J]. Liver Int,2019,39(4):598-609.
|
|
[3] QIN J,LI R,RAES J,et al. A human gut microbial gene catalogue established by metagenomic sequencing[J]. Nature,2010,464(7285):59-65.
|
|
[4] FISCHBACH MA,SONNENBURG JL. Eating for two:How metabolism establishes interspecies interactions in the gut[J].Cell Host Microbe,2011,10(4):336-347.
|
|
[5] TILG H,CANI PD,MAYER EA. Gut microbiome and liver diseases[J]. Gut,2016,65(12):2035-2044.
|
|
[6] YU X,WANG WJ,JIN JY,et al. Linggui Zhugan decoction combined with probiotics in the treatment of nonalcoholic fatty liver disease[J]. J Changchun Univ Chin Med,2019,35(5):891-894.(in Chinese)喻晓，王雯婕，金嘉悦，等．苓桂术甘汤联合益生菌治疗非酒精性脂肪肝[J]．长春中医药大学学报，2019,35(5):891-894.
|
|
[7] KIM YS,HO SB. Intestinal goblet cells and mucins in health and disease:Recent insights and progress[J]. Curr Gastroenterol Rep,2010,12(5):319-330.
|
|
[8] ARAB JP,MARTIN-MATEOS RM,SHAH VH. Gut-liver axis,cirrhosis and portal hypertension:The chicken and the egg[J]. Hepatol Int,2018,12(Suppl 1):24-33.
|
|
[9] MIYAKE Y,YAMAMOTO K. Role of gut microbiota in liver diseases[J]. Hepatol Res,2013,43(2):139-146.
|
|
[10] KOCH M. Gut microbiota and the liver:A tale of 2 cities:A narrative view in 2 acts[J]. J Clin Gastroenterol,2016,50(Suppl 2):s183-s187.
|
|
[11] SEO YS,SHAH VH. The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension[J]. Clin Mol Hepatol,2012,18(4):337-346.
|
|
[12] CARIELLO R,FEDERICO A,SAPONE A,et al. Intestinal permeability in patients with chronic liver diseases:Its relationship with the aetiology and the entity of liver damage[J]. Dig Liver Dis,2010,42(3):200-204.
|
|
[13] WANG YX,LI W,CHENG DY,et al. Characteristics of intestinal flora of patients with hepatitis B related decompensated cirrhosis[J/CD]. Chin J Exp Clin Infect Dis(Electronic Version),2019,13(2):110-116.(in Chinese)王艺璇，李炜，程丹颖，等．乙型肝炎失代偿期肝硬化患者肠道菌群特征[J/CD]．中华实验和临床感染病杂志(电子版)，2019,13(2):110-116.
|
|
[14] KAKIYAMA G,HYLEMON PB,ZHOU H,et al. Colonic inflammation and secondary bile acids in alcoholic cirrhosis[J]. Am J Physiol Gastrointest Liver Physiol,2014,306(11):g929-g937.
|
|
[15] PARSÉUS A,SOMMER N,SOMMER F,et al. Microbiota-induced obesity requires farnesoid X receptor[J]. Gut,2017,66(3):429-437.
|
|
[16] LORENZO-ZUÑIGA V,BARTOLÍR,PLANAS R,et al. Oral bile acids reduce bacterial overgrowth,bacterial translocation,and endotoxemia in cirrhotic rats[J]. Hepatology,2003,37(3):551-557.
|
|
[17] CARIOU B,STAELS B. The expanding role of the bile acid receptor FXR in the small intestine[J]. J Hepatol,2006,44(6):1213-1215.
|
|
[18] STALEY C,WEINGARDEN AR,KHORUTS A,et al. Interaction of gut microbiota with bile acid metabolism and its influence on disease states[J]. Appl Microbiol Biotechnol,2017,101(1):47-64.
|
|
[19] GADALETA RM,van ERPECUM KJ,OLDENBURG B,et al.Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease[J].Gut,2011,60(4):463-472.
|
|
[20] WAHLSTRÖM A,SAYIN SI,MARSCHALL HU,et al. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism[J]. Cell Metab,2016,24(1):41-50.
|
|
[21] KEITEL V,REINEHR R,GATSIOS P,et al. The G-protein coupled bile salt receptor TGR5 is expressed in liver sinusoidal endothelial cells[J]. Hepatology,2007,45(3):695-704.
|
|
[22] KELLY JR,KENNEDY PJ,CRYAN JF,et al. Breaking down the barriers:The gut microbiome,intestinal permeability and stress-related psychiatric disorders[J]. Front Cell Neurosci,2015,9:392.
|
|
[23] ZHOU D,PAN Q,XIN FZ,et al. Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier[J]. World J Gastroenterol,2017,23(1):60-75.
|
|
[24] CARIO E. Barrier-protective function of intestinal epithelial Toll-like receptor 2[J]. Mucosal Immunol,2008,1(Suppl1):s62-s66.
|
|
[25] WU ZW,XU KJ,LI LJ,et al. Investigation of intestinal bacterial translocation in 78 patients with cirrhosis after liver transplantation[J]. Chin J Surg,2006,44(21):1456-1459.(in Chinese)吴仲文，徐凯进，李兰娟，等．78例肝硬化患者肠道细菌易位及其相关性研究[J]．中华外科杂志，2006,44(21):1456-1459.
|
|
[26] YU HN,LIU ZH. Recent progress in intestinal microbiota and mucosal immunity[J]. Chin J Immunol,2019,35(16):1921-1930.(in Chinese)俞昊男，刘志华．肠道微生物与黏膜免疫研究的前沿进展[J]．中国免疫学杂志，2019,35(16):1921-1930.
|
|
[27] NICHOLSON JK,HOLMES E,KINROSS J,et al. Host-gut microbiota metabolic interactions[J]. Science,2012,336(6086):1262-1267.
|
|
[28] de FRANCHIS R. Expanding consensus in portal hypertension:Report of the Baveno VI Consensus Workshop:Stratifying risk and individualizing care for portal hypertension[J]. J Hepatol,2015,63(3):743-752.
|
|
[29] GARCIA-TSAO G,BOSCH J. Management of varices and variceal hemorrhage in cirrhosis[J]. N Engl J Med,2010,362(9):823-832.
|
|
[30] SENZOLO M,FRIES W,BUDA A,et al. Oral propranolol decreases intestinal permeability in patients with cirrhosis:Another protective mechanism against bleeding?[J]. Am J Gastroenterol,2009,104(12):3115-3116.
|
|
[31] REIBERGER T,FERLITSCH A,PAYER BA,et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis[J]. J Hepatol,2013,58(5):911-921.
|
|
[32] DORON S,GORBACH SL. Probiotics:Their role in the treatment and prevention of disease[J]. Expert Rev Anti Infect Ther,2006,4(2):261-275.
|
|
[33] GUPTA N,KUMAR A,SHARMA P,et al. Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices:A randomized trial[J]. Liver Int,2013,33(8):1148-1157.
|
|
[34] RINCÓN D,VAQUERO J,HERNANDO A,et al. Oral probiotic VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites[J]. Liver Int,2014,34(10):1504-1512.
|
|
[35] HUANG XY,LI GP,KOU JG,et al. Relationship between intestinal dysbacteriosis and Child-Pugh classification in patients with cirrhosis[J]. J Clin Hepatol,2015,31(3):392-395.(in Chinese)黄晓宇，李刚平，寇继光，等．肝硬化患者肠道菌群失调与Child-Pugh分级的关系[J]．临床肝胆病杂志，2015,31(3):392-395.
|
|
[36] KIMER N,PEDERSEN JS,BUSK TM,et al. Rifaximin has no effect on hemodynamics in decompensated cirrhosis:A randomized,double-blind,placebo-controlled trial[J]. Hepatology,2017,65(2):592-603.
|
|
[37] LIM YL,KIM MY,JANG YO,et al. Rifaximin and propranolol combination therapy is more effective than propranolol monotherapy for the reduction of portal pressure:An open randomized controlled pilot study[J]. Gut Liver,2017,11(5):702-710.
|
|
[38] BAJAJ JS,HEUMAN DM,SANYAL AJ,et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy[J]. PLo S One,2013,8(4):e60042.
|
|
[39] BAJAJ JS,GILLEVET PM,PATEL NR,et al. A longitudinal systems biology analysis of lactulose withdrawal in hepatic encephalopathy[J]. Metab Brain Dis,2012,27(2):205-215.
|
|
[40] RIGGIO O,VARRIALE M,TESTORE GP,et al. Effect of lactitol and lactulose administration on the fecal flora in cirrhotic patients[J]. J Clin Gastroenterol,1990,12(4):433-436.
|
|
[41] MORTENSEN PB,HOLTUG K,BONNÉN H,et al. The degradation of amino acids,proteins,and blood to short-chain fatty acids in colon is prevented by lactulose[J]. Gastroenterology,1990,98(2):353-360.
|
|
[42] RAYES N,SEEHOFER D,HANSEN S,et al. Early enteral supply of lactobacillus and fiber versus selective bowel decontamination:A controlled trial in liver transplant recipients[J].Transplantation 2002,74(1):123-127.
|
|
[43] HALILBASIC E,FUCHS C,TRAUSSNIGG S,et al. Farnesoid X receptor agonists and other bile acid signaling strategies for treatment of liver disease[J]. Dig Dis,2016,34(5):580-588.
|
|
[44] VERBEKE L,FARRE R,TREBICKA J,et al. Obeticholic acid,a farnesoid X receptor agonist,improves portal hypertension by two distinct pathways in cirrhotic rats[J]. Hepatology,2014,59(6):2286-2298.
|
|
[45]'U BEDA M,LARIO M,MUNOZ L,et al. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats[J]. J Hepatol,2016,64(5):1049-1057.
|
DownLoad: